Additionally, ADAM17 is highly expressed in EGFR-mutated NSCLC cells, where an anti-ADAM17 antibody enhances EGFR-TKI-mediated growth inhibition, which is accompanied with reduced ERK phosphorylation [90]. Here, EGFR is linked to non-small cell lung carcinoma.